Back

Melanoma Response to Immunotherapy is regulated by B Cell-Derived Extracellular Vesicles

Al Hrout, A.; Balayev, A.; Cervantes-Gracia, K.; Silina, K.; Levesque, M.; Chahwan, R.

2024-12-16 cancer biology
10.1101/2024.12.12.628150 bioRxiv
Show abstract

The immune tumor microenvironment (TME) is increasingly recognized as a dynamic ecosystem where B cells play pivotal roles in modulating therapeutic responses, particularly in the context of immune checkpoint blockade (ICB) therapy. While B cells have traditionally been viewed as bystanders in tumor immunity, recent evidence suggests they may actively influence anti-tumor immunity, albeit with conflicting reports regarding their pro-tumor or anti-tumor roles. This study explores the crucial roles played by B cells and their secreted extracellular vesicles (EVs) in shaping melanoma responses to ICB therapy. We show a significant enrichment of B cells in ICB therapy responders compared to non-responders, pre-treatment, through retrospective analyses of melanoma patient tumors. Functional assays demonstrate that B cell depletion impairs T cell-mediated tumor cytotoxicity, underscoring the importance of B cells in anti-tumor responses. To investigate the clinical relevance, EVs were isolated from melanoma patient tumors, and fractioned into tumor and immune subpopulations. MiRNA profiling of CD19+ EVs identifies miR-99a-5p as a top candidate, among several others, upregulated in responders. Functional assays show that miR-99a-5p silencing in B cells diminishes T cell-mediated anti-tumor activity, suggesting its role in promoting B cell-mediated immune responses. Mechanistically, miR-99a-5p influences B cell maturation within the TME by mediating class-switch recombination. Our findings highlight the important role of B cells and their derived EVs in shaping the efficacy of melanoma immunotherapy, paving the way for novel therapeutic strategies targeting B cell-related pathways. Graphical abstract (created with Biorender) O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=177 SRC="FIGDIR/small/628150v1_ufig1.gif" ALT="Figure 1"> View larger version (60K): org.highwire.dtl.DTLVardef@144bbe6org.highwire.dtl.DTLVardef@18c1e9eorg.highwire.dtl.DTLVardef@2e37aaorg.highwire.dtl.DTLVardef@487e18_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Cancers
200 papers in training set
Top 0.4%
10.1%
2
Cancer Immunology, Immunotherapy
11 papers in training set
Top 0.1%
8.4%
3
OncoImmunology
22 papers in training set
Top 0.1%
4.9%
4
Frontiers in Immunology
586 papers in training set
Top 1%
4.9%
5
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.3%
4.2%
6
Cell Reports
1338 papers in training set
Top 14%
3.6%
7
iScience
1063 papers in training set
Top 5%
3.6%
8
Cancer Immunology Research
34 papers in training set
Top 0.1%
3.6%
9
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 2%
3.1%
10
Theranostics
33 papers in training set
Top 0.4%
2.1%
11
Computational and Structural Biotechnology Journal
216 papers in training set
Top 3%
2.1%
50% of probability mass above
12
Cell Reports Medicine
140 papers in training set
Top 3%
2.1%
13
Nature Communications
4913 papers in training set
Top 47%
2.1%
14
Cancer Research Communications
46 papers in training set
Top 0.3%
1.9%
15
International Journal of Molecular Sciences
453 papers in training set
Top 6%
1.8%
16
Cell Communication and Signaling
35 papers in training set
Top 0.4%
1.8%
17
PLOS ONE
4510 papers in training set
Top 54%
1.7%
18
eLife
5422 papers in training set
Top 42%
1.7%
19
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.1%
1.7%
20
Cancer Research
116 papers in training set
Top 2%
1.7%
21
Journal of Extracellular Vesicles
50 papers in training set
Top 0.2%
1.5%
22
Scientific Reports
3102 papers in training set
Top 64%
1.3%
23
Antibody Therapeutics
16 papers in training set
Top 0.3%
1.3%
24
npj Systems Biology and Applications
99 papers in training set
Top 2%
1.2%
25
Cancer Cell
38 papers in training set
Top 1%
1.2%
26
Frontiers in Oncology
95 papers in training set
Top 3%
0.9%
27
Cells
232 papers in training set
Top 6%
0.8%
28
Journal of Translational Medicine
46 papers in training set
Top 3%
0.7%
29
EBioMedicine
39 papers in training set
Top 1%
0.7%
30
EMBO reports
136 papers in training set
Top 6%
0.7%